These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

844 related items for PubMed ID: 19358835

  • 21. Gelatinase A (MM-2), gelatinase B (MMP-9) and their inhibitors (TIMP 1, TIMP-2) in serum of women with endometriosis: Significant correlation between MMP-2, MMP-9 and their inhibitors without difference in levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in relation to the severity of endometriosis.
    Salata IM, Stojanovic N, Cajdler-Łuba A, Lewandowski KC, Lewiński A.
    Gynecol Endocrinol; 2008 Jun; 24(6):326-30. PubMed ID: 18584412
    [Abstract] [Full Text] [Related]

  • 22. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M.
    Anticancer Res; 2007 Jun; 27(4C):2753-8. PubMed ID: 17695443
    [Abstract] [Full Text] [Related]

  • 23. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A, Höyhtyä M, Tavelin B, Stenling R, Lindmark G.
    Anticancer Res; 2000 Jun; 20(2B):1085-91. PubMed ID: 10810401
    [Abstract] [Full Text] [Related]

  • 24. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R, Jacob-Ferreira AL, Joviliano EE, Tanus-Santos JE, Evora PR.
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
    Hoffmann U, Bertsch T, Dvortsak E, Liebetrau C, Lang S, Liebe V, Huhle G, Borggrefe M, Brueckmann M.
    Scand J Infect Dis; 2006 Apr; 38(10):867-72. PubMed ID: 17008230
    [Abstract] [Full Text] [Related]

  • 27. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M.
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis.
    Mühl D, Nagy B, Woth G, Falusi B, Bogár L, Weber G, Lantos J.
    J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151
    [Abstract] [Full Text] [Related]

  • 31. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis.
    Ichiyama T, Siba P, Suarkia D, Takasu T, Miki K, Kira R, Kusuhara K, Hara T, Toyama J, Furukawa S.
    J Neurol Sci; 2007 Jan 15; 252(1):45-8. PubMed ID: 17118404
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Mercury exposure increases circulating net matrix metalloproteinase (MMP)-2 and MMP-9 activities.
    Jacob-Ferreira AL, Passos CJ, Jordão AA, Fillion M, Mergler D, Lemire M, Gerlach RF, Barbosa F, Tanus-Santos JE.
    Basic Clin Pharmacol Toxicol; 2009 Oct 15; 105(4):281-8. PubMed ID: 19594729
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV, Savenkova OV, Kondakova IV, Perel'muter VM, Choĭnzonov EL, Shishkin DA.
    Vopr Onkol; 2007 Oct 15; 53(1):26-31. PubMed ID: 17649730
    [Abstract] [Full Text] [Related]

  • 38. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls.
    Stojanovic N, Lewandowski K, Salata I, Bienkiewicz M, Tuck S, Prelevic G, Press M.
    Gynecol Endocrinol; 2010 Mar 15; 26(3):201-7. PubMed ID: 19526397
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
    Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T.
    Eur J Haematol; 2008 Jan 15; 80(1):46-54. PubMed ID: 18028436
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.